Mary Di Biase X4 Pharmaceuticals, Inc (XFOR) insider trading activity

XFOR Quotes by TradingView

Mary Di Biase is Chief Operating Officer of X4 Pharmaceuticals, Inc. Currently has a direct ownership of 1.14 Million shares of XFOR, which is worth approximately $536,260. The most recent transaction as insider was on Feb 12, 2025, when has been sold 650,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.14M
152.4% 3M change
271.46% 12M change
Total Value Held $536,260

Mary DiBiase Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 12 2025
BUY
Grant, award, or other acquisition
-
650,000 Added 36.29%
1,140,980 Common Stock
Jan 24 2025
SELL
Open market or private sale
$10,016 $0.45 p/Share
22,258 Reduced 4.34%
490,980 Common Stock
Jan 23 2025
BUY
Grant, award, or other acquisition
-
61,178 Added 10.65%
513,238 Common Stock
Oct 07 2024
SELL
Open market or private sale
$38,586 $0.57 p/Share
67,695 Reduced 13.02%
452,060 Common Stock
Oct 04 2024
BUY
Grant, award, or other acquisition
-
230,645 Added 30.74%
519,755 Common Stock
Sep 09 2024
SELL
Open market or private sale
$1,743 $0.66 p/Share
2,642 Reduced 0.91%
289,110 Common Stock
Mar 11 2024
SELL
Open market or private sale
$13,559 $0.88 p/Share
15,409 Reduced 5.02%
291,752 Common Stock
Feb 12 2024
SELL
Open market or private sale
$3,719 $1.01 p/Share
3,683 Reduced 1.18%
307,161 Common Stock
Nov 01 2023
SELL
Open market or private sale
$49,417 $0.73 p/Share
67,695 Reduced 17.88%
310,844 Common Stock
Oct 31 2023
BUY
Grant, award, or other acquisition
-
230,645 Added 37.86%
378,539 Common Stock
Sep 08 2023
SELL
Open market or private sale
$3,302 $1.25 p/Share
2,642 Reduced 1.76%
147,894 Common Stock
Jun 30 2023
SELL
Open market or private sale
$876 $1.89 p/Share
464 Reduced 0.31%
150,536 Common Stock
Jun 23 2023
SELL
Open market or private sale
$1,654 $1.93 p/Share
857 Reduced 0.56%
151,000 Common Stock
Jun 15 2023
SELL
Open market or private sale
$1,911 $2.23 p/Share
857 Reduced 0.56%
151,857 Common Stock
Mar 10 2023
SELL
Open market or private sale
$15,281 $0.84 p/Share
18,192 Reduced 10.64%
152,714 Common Stock
Feb 13 2023
SELL
Open market or private sale
$4,043 $0.93 p/Share
4,348 Reduced 2.48%
170,906 Common Stock
Aug 17 2022
SELL
Open market or private sale
-
1,713 Reduced 0.95%
177,896 Common Stock
Jun 30 2022
SELL
Open market or private sale
-
1,578 Reduced 0.87%
179,609 Common Stock
Jun 24 2022
SELL
Open market or private sale
-
856 Reduced 0.47%
181,187 Common Stock
Jun 16 2022
SELL
Open market or private sale
-
856 Reduced 0.47%
182,043 Common Stock
Mar 01 2022
BUY
Grant, award, or other acquisition
-
105,000 Added 36.47%
182,899 Common Stock
Feb 11 2022
SELL
Open market or private sale
-
12,545 Reduced 13.87%
77,899 Common Stock
Sep 08 2021
BUY
Grant, award, or other acquisition
-
27,000 Added 22.99%
90,444 Common Stock
MD

Mary Di Biase

Chief Operating Officer
Boston, MA

Track Institutional and Insider Activities on XFOR

Follow X4 Pharmaceuticals, Inc and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells XFOR shares.

Notify only if

Insider Trading

Get notified when an X4 Pharmaceuticals, Inc insider buys or sells XFOR shares.

Notify only if

News

Receive news related to X4 Pharmaceuticals, Inc

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on XFOR